Misplaced Pages

FV-100: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 20:33, 19 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit Latest revision as of 11:22, 27 December 2024 edit undoCitation bot (talk | contribs)Bots5,417,087 edits Added work. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar 
(34 intermediate revisions by 25 users not shown)
Line 1: Line 1:
{{Orphan|date=April 2011}}

{{chembox {{chembox
| Verifiedfields = changed
| verifiedrevid = 415900961 | verifiedrevid = 424911420
|ImageFile=Cf1743.png | ImageFile=Cf1743.png
|ImageSize=200px | ImageSize=200px
⚫ |IUPACName=3--6-(4-pentylphenyl)furopyrimidin-2-one
| IUPACName=3-(2-Deoxy-β-<small>D</small>-''erythro''-pentofuranosyl)-6-(4-pentylphenyl)furopyrimidin-2(3''H'')-one
⚫ |OtherNames=Cf1743
⚫ | SystematicName=3--6-(4-pentylphenyl)furopyrimidin-2(3''H'')-one
⚫ | OtherNames=Cf1743
|Section1={{Chembox Identifiers |Section1={{Chembox Identifiers
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=
| CASNo= 956483-02-6
⚫ | PubChem=493485
| ChEMBL = 344738
⚫ | SMILES=CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)4C((O4)CO)O
| ChemSpiderID = 431897
⚫ | PubChem=493485
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0NJ5F6D4U7
| StdInChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
| StdInChIKey = MFGSDSRTGUVZQG-DFQSSKMNSA-N
⚫ | SMILES=CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)4C((O4)CO)O
}} }}
|Section2={{Chembox Properties |Section2={{Chembox Properties
| C=22 | H=26 | N=2 | O=5 | C=22 | H=26 | N=2 | O=5
| Appearance= | Appearance=
| Density= | Density=
| MeltingPt= | MeltingPt=
| BoilingPt= | BoilingPt=
| Solubility= | Solubility=
}} }}
|Section3={{Chembox Hazards |Section3={{Chembox Hazards
| MainHazards= | MainHazards=
| FlashPt= | FlashPt=
| AutoignitionPt =
| Autoignition=
}} }}
}} }}


'''FV-100''', also known as '''Cf1743''', is an orally available nucleoside analogue drug<ref>{{cite |url=http://www.medicalnewstoday.com/articles/138537.php |title=Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies |year=2009 }}</ref> with antiviral activity.<ref>{{cite journal | doi = 10.1093/jac/dkp294 | author = McGuigan, Christopher; Balzarini, Jan | title = FV100 as a new approach for the possible treatment of varicella-zoster virus infection | journal = Journal of Antimicrobial Chemotherapy | year = 2009 | volume = 64 | issue = 4 | pages = 671–673 | pmid = 19679595}}</ref> It may be effective against ].<ref>{{cite |url=http://www.dailymail.co.uk/health/article-515969/Thousands-spared-pain-shingles.html |quote="And at Cardiff University, Chris McGuigan, professor of medicinal chemistry, has developed a new drug for shingles, FV-100, which is doing well in phase I trials. FV 100 looks like it will be very potent (more than 10,000 times as strong as aciclovir), safe and could prevent long-term pain, too. It could be on the market by 2010." |year=2010 }}</ref> '''FV-100''', also known as '''Cf1743''', is an orally available ] drug<ref>{{citation |url=http://www.medicalnewstoday.com/articles/138537.php |title=Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies |year=2009 }}</ref> with ] activity.<ref>{{cite journal | doi = 10.1093/jac/dkp294 |author1=McGuigan, Christopher |author2=Balzarini, Jan | title = FV100 as a new approach for the possible treatment of varicella-zoster virus infection | journal = ] | year = 2009 | volume = 64 | issue = 4 | pages = 671–673 | pmid = 19679595| doi-access = free }}</ref> It may be effective against ].<ref>Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. ''J Med Virol''. 2017 Jul;89(7):1255-1264. {{doi|10.1002/jmv.24750}} {{PMID|27943311}}</ref>


It was discovered in 1999.<ref>{{cite |url=http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html |title=Step forward for shingles drug - FV100 }} Shows structure of FV100</ref> It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.<ref>{{citation |url=http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html |title=Step forward for shingles drug - FV100. |author1=Cardiff School of Pharmacy |author2=Pharmaceutical Sciences }} Shows structure of FV100.</ref>


==Clinical trials== ==Clinical trials==
It is in a ] against ] in patients with ].<ref>{{cite |url=http://clinicaltrials.gov/ct2/show/NCT00900783 |title=A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster }}</ref> FV-100 was tested against ] in a ] in patients with ]. The trial was sponsored by Bristol-Myers Squibb.<ref>{{citation |url=http://clinicaltrials.gov/ct2/show/NCT00900783 |title=A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster |date=23 September 2015 }}</ref> The drug is currently being developed by , ].<ref>{{citation |url= http://www.dddmag.com/news/2015/01/contravir-pharmaceuticals-fda-meeting-about-antiviral-drug-trial?et_cid=4352306&et_rid=297252576&type=cta| title=ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.| work=Drug Discovery & Development| date=January 2015 }}</ref> It has reached Phase III clinical trials.<ref>De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. ''Clin Microbiol Rev''. 2016 Jul;29(3):695-747. {{doi|10.1128/CMR.00102-15}} {{PMID|27281742}}</ref>


==References== ==References==
{{reflist}} {{reflist}}


{{Antivirals}}

]
] ]
] ]
] ]
]




{{pharma-stub}} {{antiinfective-drug-stub}}